NASDAQ:FLGT

Fulgent Genetics (FLGT) Stock Forecast, Price & News

$26.82

-0.37 (-1.36%)

(As of 09/28/2023 ET)

Compare

Today's Range: $26.75
▼
$27.34
50-Day Range: $27.19
▼
$40.23
52-Week Range: $26.75
▼
$44.09

Volume: 211,295 shs
Average Volume: 219,436 shs
Market Capitalization: $802.72 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $42.33

Fulgent Genetics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 57.8% Upside
$42.33 Price Target
Short Interest: Healthy
2.89% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.67
Upright™ Environmental Score
News Sentiment: 0.99
Based on 3 Articles This Week
Insider Trading: Selling Shares
$542,598 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($2.10) to ($1.90) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.83 out of 5 stars

Medical Sector

65th out of 969 stocks

Medical Laboratories Industry

3rd out of 25 stocks

3.3

Analyst's Opinion

Consensus Rating
Fulgent Genetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $42.33, Fulgent Genetics has a forecasted upside of 57.8% from its current price of $26.82.
Amount of Analyst Coverage
Fulgent Genetics has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
2.89% of the float of Fulgent Genetics has been sold short.
Short Interest Ratio / Days to Cover
Fulgent Genetics has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Fulgent Genetics has recently decreased by 8.04%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Fulgent Genetics does not currently pay a dividend.
Dividend Growth
Fulgent Genetics does not have a long track record of dividend growth.

4.1

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Fulgent Genetics has received a 58.06% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Private genetic testing services", "Private infectious disease diagnostics services", and "Private medical laboratory services" products. See details.
Environmental Sustainability
The Environmental Impact score for Fulgent Genetics is -0.67.

3.3

News and Social Media Coverage

News Sentiment
Fulgent Genetics has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Fulgent Genetics this week, compared to 2 articles on an average week.
Search Interest
19 people have searched for FLGT on MarketBeat in the last 30 days. This is an increase of 73% compared to the previous 30 days.
MarketBeat Follows
Only 6 people have added Fulgent Genetics to their MarketBeat watchlist in the last 30 days. This is a decrease of -14% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Fulgent Genetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $542,598.00 in company stock.
Percentage Held by Insiders
31.76% of the stock of Fulgent Genetics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
46.09% of the stock of Fulgent Genetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Fulgent Genetics are expected to grow in the coming year, from ($2.10) to ($1.90) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Fulgent Genetics is -16.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Fulgent Genetics is -16.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Fulgent Genetics has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Fulgent Genetics (NASDAQ:FLGT) Stock

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and next generation sequencer services related to hereditary cancer, cardiovascular genetics, reproductive health, and neurodegenerative genetics, as well as pharmacogenetic tests. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to enhance the therapeutic window and pharmacokinetic profile, or PK profile, of new and existing cancer drugs. The company also operates picture genetics platform which includes proprietary gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.

FLGT Price History

30 days | 90 days | 365 days | Advanced Chart

FLGT Stock News Headlines

September 21, 2023 | msn.com

Fulgent Genetics: Navigating Post-COVID Growing Pains

August 5, 2023 | finance.yahoo.com

Fulgent Genetics, Inc. (NASDAQ:FLGT) Q2 2023 Earnings Call Transcript

September 29, 2023 | Tradewins (Ad)

Successful Options Trading Begins With…

Options trading expert Wendy Kirkland’s free guide reveals the options trading principles that are as easy to implement as they are to learn and how using them could earn you thousands in extra income each month!

August 4, 2023 | finance.yahoo.com

Q2 2023 Fulgent Genetics Inc Earnings Call

August 4, 2023 | finance.yahoo.com

Fulgent Reports Second Quarter 2023 Financial Results

August 4, 2023 | finance.yahoo.com

Fulgent Genetics, Inc. (FLGT) Reports Q2 Loss, Tops Revenue Estimates

August 3, 2023 | seekingalpha.com

Fulgent Genetics Q2 2023 Earnings Preview

July 29, 2023 | msn.com

Fulgent Genetics: Post-Pandemic Devaluing Appears Overdone

September 29, 2023 | The Oxford Club (Ad)

Better Than Oil Stocks?

The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.

July 28, 2023 | finance.yahoo.com

FLGT - Fulgent Genetics, Inc.

July 18, 2023 | finance.yahoo.com

Fulgent Genetics to Announce Second Quarter 2023 Financial Results on Friday, August 4, 2023

June 6, 2023 | finance.yahoo.com

Got $2,500? This Dirt Cheap Growth Stock Could Be Worth Buying Hand Over Fist

June 5, 2023 | finance.yahoo.com

Fulgent Data at ASCO 2023 Highlights Progress for Its Lead Therapeutic Oncology Candidate, FID-007, in Various Cancers

May 23, 2023 | finance.yahoo.com

2 Undervalued Stocks to Buy for Potentially Massive Gains in the Next 10 Years

May 23, 2023 | finance.yahoo.com

Better Diversified Biotech Stock: 23andMe vs. Fulgent Genetics

May 19, 2023 | msn.com

Fulgent Genetics Earnings Perspective: Return On Capital Employed

May 18, 2023 | finance.yahoo.com

Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2023 Annual Meeting

May 14, 2023 | msn.com

What To Expect From Fulgent Genetics In 2023

May 8, 2023 | finance.yahoo.com

3 Cash-Rich Biotechs in a Market That's Tough on the Debt Burdened

May 5, 2023 | finance.yahoo.com

Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Tops Revenue Estimates

May 5, 2023 | finance.yahoo.com

Fulgent Reports First Quarter 2023 Financial Results

May 4, 2023 | msn.com

Fulgent Genetics Q1 2023 Earnings Preview

May 4, 2023 | msn.com

Preview: Fulgent Genetics's Earnings

April 20, 2023 | finance.yahoo.com

Fulgent Genetics to Announce First Quarter 2023 Financial Results on Friday May 5, 2023

April 18, 2023 | morningstar.com

Fulgent Genetics Inc FLGT Stock Quote

April 14, 2023 | finance.yahoo.com

Returns Are Gaining Momentum At Fulgent Genetics (NASDAQ:FLGT)

April 12, 2023 | msn.com

Are Medical Stocks Lagging Fulgent Genetics (FLGT) This Year?

See More Headlines

Receive FLGT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fulgent Genetics and its competitors with MarketBeat's FREE daily newsletter.

FLGT Company Calendar

Last Earnings: 8/04/2023
Today: 9/29/2023
Next Earnings (Estimated): 11/06/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Medical laboratories
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:FLGT
CUSIP: N/A
CIK: 1674930
Web: www.fulgentgenetics.com
Phone: (626) 350-0537
Fax: 626-454-1667
Employees: 1,012
Year Founded: 2011

Price Target and Rating

Average Stock Price Forecast: $42.33
High Stock Price Forecast: $45.00
Low Stock Price Forecast: $37.00
Forecasted Upside/Downside: +57.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.64)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $143.40 million
Net Margins: -15.84%
Pretax Margin: -21.94%
Return on Equity: -3.29%
Return on Assets: -3.03%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.15
Quick Ratio: 8.15

Sales & Book Value

Annual Sales: $618.97 million
Price / Sales: 1.30
Cash Flow: $6.42 per share
Price / Cash Flow: 4.18
Book Value: $43.14 per share
Price / Book: 0.62

Miscellaneous

Outstanding Shares: 29,930,000
Free Float: 20,422,000
Market Cap: $802.72 million
Optionable: Not Optionable
Beta: 1.52

Social Links

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Mr. Ming Hsieh (Age 67)
Chairman & CEO
Comp: $1.66M

Mr. Jian Xie (Age 57)
COO & Pres
Comp: $755.73k

Mr. Paul Kim (Age 56)
Chief Financial Officer
Comp: $757.59k

Dr. Han Lin Gao D.A.B.M.G. (Age 56)
F.A.C.M.G., FACMG, M.D., Ph.D., Chief Scientific Officer & Laboratory Director
Comp: $630.61k

Ms. Natalie Prescott
Gen. Counsel & Chief Privacy Officer

Ms. Doreen Ng
VP of Operations & Compliance and GM of Houston Office

Mr. Jakub Sram
VP of Bus. Devel. & Sales

Ms. Ellen Tsui
VP of HR

Mr. Brandon Perthuis
Chief Commercial Officer

Dr. Lawrence M. Weiss M.D. (Age 66)
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

FLGT Stock - Frequently Asked Questions

Should I buy or sell Fulgent Genetics stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" FLGT shares.
View FLGT analyst ratings or view top-rated stocks.
What is Fulgent Genetics' stock price forecast for 2023?: 3 analysts have issued 12 month price targets for Fulgent Genetics' shares. Their FLGT share price forecasts range from $37.00 to $45.00. On average, they expect the company's stock price to reach $42.33 in the next twelve months. This suggests a possible upside of 57.8% from the stock's current price.
View analysts price targets for FLGT or view top-rated stocks among Wall Street analysts.
How have FLGT shares performed in 2023?: Fulgent Genetics' stock was trading at $29.78 at the beginning of 2023. Since then, FLGT stock has decreased by 9.9% and is now trading at $26.82.
View the best growth stocks for 2023 here.
Are investors shorting Fulgent Genetics?: Fulgent Genetics saw a decrease in short interest during the month of September. As of September 15th, there was short interest totaling 549,800 shares, a decrease of 8.0% from the August 31st total of 597,900 shares. Based on an average daily trading volume, of 207,800 shares, the days-to-cover ratio is currently 2.6 days. Approximately 2.9% of the shares of the stock are short sold.
View Fulgent Genetics' Short Interest.
When is Fulgent Genetics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our FLGT earnings forecast.
How were Fulgent Genetics' earnings last quarter?: Fulgent Genetics, Inc. (NASDAQ:FLGT) announced its earnings results on Friday, August, 4th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.59) by $0.26. The firm had revenue of $67.85 million for the quarter, compared to the consensus estimate of $62.68 million. Fulgent Genetics had a negative net margin of 15.84% and a negative trailing twelve-month return on equity of 3.29%.
What ETFs hold Fulgent Genetics' stock?: ETFs with the largest weight of Fulgent Genetics (NASDAQ:FLGT) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM), ROBO Global Healthcare Technology and Innovation ETF (HTEC), SPDR S&P Health Care Services ETF (XHS), Global X Genomics & Biotechnology ETF (GNOM) and Invesco S&P SmallCap Health Care ETF (PSCH).First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).
What guidance has Fulgent Genetics issued on next quarter's earnings?: Fulgent Genetics issued an update on its FY 2023 earnings guidance on Friday, August, 4th. The company provided earnings per share guidance of -$0.95--$0.95 for the period, compared to the consensus earnings per share estimate of -$0.34. The company issued revenue guidance of -.

What other stocks do shareholders of Fulgent Genetics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Fulgent Genetics investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), NeoGenomics (NEO), Invitae (NVTA), Block (SQ), JD.com (JD), Marvell Technology (MRVL), Teladoc Health (TDOC) and Editas Medicine (EDIT).
When did Fulgent Genetics IPO?: (FLGT) raised $60 million in an IPO on Thursday, September 29th 2016. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Credit Suisse and Piper Jaffray acted as the underwriters for the IPO and Raymond James and BTIG were co-managers.
What is Fulgent Genetics' stock symbol?: Fulgent Genetics trades on the NASDAQ under the ticker symbol "FLGT."
How do I buy shares of Fulgent Genetics?: Shares of FLGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Fulgent Genetics' stock price today?: One share of FLGT stock can currently be purchased for approximately $26.82.
How much money does Fulgent Genetics make?: Fulgent Genetics (NASDAQ:FLGT) has a market capitalization of $802.72 million and generates $618.97 million in revenue each year. The company earns $143.40 million in net income (profit) each year or ($1.64) on an earnings per share basis.
How many employees does Fulgent Genetics have?: The company employs 1,012 workers across the globe.
Does Fulgent Genetics have any subsidiaries?: The following companies are subsidiares of Fulgent Genetics: CSI, Cytometry Specialists Inc., FF Gene Biotech, Fulgent Investment Development Limited, Fulgent Therapeutics LLC, and Inform Diagnostics.
Read More
How can I contact Fulgent Genetics?: Fulgent Genetics' mailing address is 4978 SANTA ANITA AVENUE, TEMPLE CITY CA, 91780. The official website for the company is www.fulgentgenetics.com. The company can be reached via phone at (626) 350-0537, via email at nborsje@blueshirtgroup.com, or via fax at 626-454-1667.

This page (NASDAQ:FLGT) was last updated on 9/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Fulgent Genetics (FLGT) Stock Forecast, Price & News

Fulgent Genetics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Fulgent Genetics (NASDAQ:FLGT) Stock

FLGT Price History

FLGT Stock News Headlines

FLGT Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

FLGT Stock - Frequently Asked Questions

Overall MarketRank^™